Abstract: Methods for treating or preventing kidney diseases and fibrosis, such as chronic kidney disease (CKD), kidney fibrosis, heart fibrosis, uterine fibrosis, and cystic fibrosis, with compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.

Abstract: The treatment of diastolic dysfunction in a subject and, in particular, compositions for use and methods in treating diastolic dysfunction are disclosed. In one aspect, the disclosure provides a composition for use comprising a therapeutically effective amount of a substance that increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject. In particular, the composition for use according to the disclosure comprises a therapeutically effective amount of the alpha B crystalline protein. It was found that the composition for use is capable of treating diastolic dysfunction and diastolic heart disease in subjects with failing hearts that have a higher cardiomyocyte stiffness than controls. Particularly, addition of alpha B crystalline reduced the higher stiffness of failing cardiomyocytes to the level observed in control cardiomyocytes.

Abstract: A nasal spray solution of the present invention includes a Povidone iodine solution; a Vitamin D liquid, Polysorbate 80 nf, Xylitol NF, water sterile, Sodium hydroxide 10% solution, and Polysaccharide 1% solution, wherein 1% solution further includes a gellan gum and a carrageenan, used as carriers to deliver liquids to cells of human and act as entrapment within a polymeric coating to block virus uptake into the cells, inactivate the virus, and protect a lining of an upper respiratory pathways against COVID-19 and SARS.

Abstract: A pharmaceutical composition in the form of an emulsion, in particular an oil-in-water emulsion, comprising certain polyunsaturated long-chain ketones and polysorbate. The composition may be used to treat or prevent certain inflammatory or proliferative conditions.

Abstract: The present invention relates to novel black cumin extract compositions and a green process for making the composition. The black cumin extract composition of the invention can be used to treat anxiety, sleep and stress disorders along with significant effect on memory enhancement. The composition is available in oil and powder forms.

Abstract: The present invention relates to the non-therapeutic cosmetic use of derivatives of 4-(3-ethoxy-4-hydroxyphenyl)alkyl ketone of formula (I) in which: R1 represents a C1-C4 alkyl radical; R2 represents a hydrogen atom, or a saturated or unsaturated, linear or branched C1-C6 hydrocarbon-based radical; R3 represents a saturated or unsaturated, linear or branched C1-C4 hydrocarbon-based radical optionally substituted by a hydroxyl group; C—X represents C?O or CH—OH; as agent for soothing the skin of the face and/or body.

Abstract: The present invention concerns the use of compounds for preventing and/or treating diabetes, for modulating glucose, insulin, and/or triglyceride levels; for reducing blood glucose level; for maintaining or increasing insulin level; for increasing insulin secretion; increasing insulin sensitivity; or decreasing insulin resistance in a subject. These novel uses have been found for compounds represented by Formula I and pharmaceutically acceptable salts. wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(0)-(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH.

Abstract: A compound of formula (I) R-L-CO—X??(I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO wherein L comprises at least one heteroatom in the backbone of the linking group; and X is an electron withdrawing group) or a salt thereof for use in the treatment of dermatitis.

Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract: A topical vitamin D and UBIQUINOL supplement composition useful in treating oral inflammation and reducing oxidative stress comprising: a supplement mixture of vitamin D and UBIQUINOL in an aqueous-free emulsion containing: spilanthes extract, stabilizing compositions for UBIQUINOL and trans-oral mucosal absorption facilitators for the supplement mixture; where the emulsion forms a mucoadhesive gel in the presence of saliva, that effects passive diffusion through the oral mucosa of the supplement mixture and spilanthes extract regulating: in vivo availability and immune response of the supplement mixture, and maintaining adequate levels of circulating vitamin D and of adjunctively administered UBIQUINOL, while minimizing the risk of hypercalcemia.

Abstract: The turgidity of potato tubers and other root vegetables is improved, maintained, or restored and/or the greening of potato tubers is delayed, prevented or inhibited and/or internal diseases caused by fungi and bacteria are prevented or treated by the application of one or more ?,?-unsaturated aliphatic aldehydes and ketones, C3 to C14 aliphatic aldehydes and ketones, and/or C3 to C7 saturated or unsaturated primary and secondary aliphatic alcohols.

Abstract: The present invention relates to a selectively purified tanshinone compounds containing extract from the root of a Salvia spp comprising Cryptotanshinone, Dihydrotanshinone, Tanshinone I, and Tanshinone IIA. It comprises at least 15%, by weight of the said identified tanshinone compounds and at least 4% by weight, of cryptotanshinone. The extract and formulations thereof have been found to exhibit excellent anti-microbial properties against, in particular MRSA.

Abstract: Disclosed herein is an eco-friendly, non-aqueous and stable antimicrobial solution composition comprising (a) about 0.1 to 20.0 wt % of a Tropolone; and (b) about 80.0 to 99.9 wt % of bio-derived 1,3-propanediol and/or bio-derived sorbitan caprylate. Also disclosed is a process for preparing and method of using the composition. The composition is stable for at least two years at room temperature and can be employed in the fields of cosmetic, toiletry, personal care, household, cleaning, disinfecting, food, beverages, enzyme formulations, feminine care products, foot care products, pet care products, food ingredients, paints, coatings, metal working fluids, nutrients for plants, construction and/or laundry products.

Abstract: The present invention is directed to a novel compound, 2-mercapto-5-methyl-4-heptanone, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a medicinal product, and toothpaste comprising the step of incorporating an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone, and a process of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone.

Abstract: Provided herein are methods for improving negative effects of ALS, AD, or ischemia, the methods comprising administering to a subject in need thereof a therapeutically effective amount of GGA, preferably present in the trans form, or a derivative thereof.

Abstract: A device and method for stimulating nerves. In one application, the approaches treat nausea and vomiting caused by a reaction to general anesthesia. A bi-modal approach involving acustimulation and medicants is contemplated for specific conditions.

Abstract: The disclosure is capsules containing an active arthropod agent and to methods of making and using the same. The active arthropod agent can be a fatty acid having six or more carbon atoms. The capsules have a polymeric wall that controls the release of the active arthropod agent. The active agent can repellent, impair and/or kill insects.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection.

Abstract: Control or repellency of biting arthropods, particularly biting insects, is accomplished by bringing the biting arthropods into contact with combinations of compounds identical or related to those found on human/animal skin or in plants acting synergistically with one another, or in combination with conventional repellents like DEET®, para-menthane-3,8-diol (PMD), sec-butyl-2-(2-hydroxyethyl) piperidine carboxylate (“Picaridin”), or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds, or any synergistic combination of DEET®, PMD, Picaridin, or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds.

Abstract: The present invention relates to a cosmetic method for treating and/or preventing greasy skin or greasiness-prone skin and/or the associated cutaneous aesthetic defects, comprising the topical application to the skin of a composition comprising, in a cosmetically acceptable medium, at least one compound of formula (I): in which: R represents a hydrogen atom or a saturated or unsaturated and linear or branched C1-C6 hydrocarbon radical; R? represents a saturated or unsaturated and linear or branched C1-C18 hydrocarbon radical, optionally substituted by a hydroxyl group; C—X represents C?O or CH—OH.

Abstract: Method of treating hypertension with a trans-aconitic acid containing composition (e.g., a water extract derived from a monocotyledon plant).

Abstract: In various embodiments, the present disclosure provides a method and enzyme for forming various compounds, such as monoterpenes and monoterpenoid compounds. In a specific example, the present disclosure provides a method for producing one or more of (?)-ipsdienol, (?)-ipsenol, ipsenone, and ipsdienone. The present disclosure also provides methods of using compounds formed from the disclosed method and enzyme.

Abstract: Compositions (3) and methods of using such compositions (3) to condition, clean, or disinfect the flow path of a conduit (8) of a microfluidic devices (16), such as flow cytometers or liquid chromatographs.

Abstract: Provided are compositions and methods for modulating quorum sensing in microbes. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing. The compounds are useful for modulating quorum sensing in bacteria and can be used in methods for prophylaxis or therapy of bacterial infections and for reduction of biofilms.

Abstract: The disclosure provides compounds useful as insect repellents and compositions comprising such repellents. The disclosure further provides insect traps.

Abstract: An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.

Abstract: A composition for treating disordered conditions in association with glucokinase activity contains a glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm contains D-psicose and/or D-tagatose as the active ingredient or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and/or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity.

Abstract: Topoisomerase inhibitors are useful for the treatment of inflammatory disorders including arthritis, restenosis, surgical adhesions and other diseases. Controlled release polymeric formulations to topoisomerase inhibitors are particularly suitable for this use.

Abstract: Compositions (3) and methods of using such compositions (3) to condition, clean, or disinfect the flow path of a conduit (8) of a microfluidic devices (16), such as flow cytometers or liquid chromatographs.

Abstract: A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.

Abstract: Compositions (3) and methods of using such compositions (3) to condition, clean, or disinfect the flow path of a conduit (8) of a microfluidic devices (16), such as flow cytometers or liquid chromatographs.

Abstract: The disclosure provides for methods of repelling, directing, altering the behavior, and controlling an insect by utilizing a compound or composition described herein. The disclosure also provides for methods of promoting the health of an insect by repelling a pest that preys on insect and/or by providing an antibiotic or nutritional supplement composition to an insect. The disclosure also provides for a composition including at least one repelling, controlling, or directing compound or composition described herein together with an insecticide, herbicide, fungicide, or miticide. Compounds, compositions, seeds, and plants useful in these methods are also described.

Abstract: The disclosure provides for methods of repelling, directing, altering the behavior, and/or controlling an insect by utilizing a compound or composition described herein. The disclosure also provides for methods of repelling or directing an insect from an organism, article, or structure by utilizing a compound or composition described herein. The disclosure also provides for an article or structure treated with a composition including at least one repellent, controlling, or directing compound described herein.

Abstract: Provide herein are intranasal compositions which include geranylgeranyl acetone (GGA) and/or derivatives thereof and methods for treating a neural disease, disorder or condition with the same.

Abstract: Compositions including (a) a pollinating insect repelling, controlling, or directing compound or composition and (b) a compound or composition capable of protecting seeds, plant parts, or plants against insect and/or nematode infestation are provided. The disclosure also provides for methods of repelling, controlling, or directing a pollinating insect, for example a bee, while protecting seeds, plant parts, and/or plants against insect and/or nematode infestation. Seeds, plants, and plant parts treated with compositions described herein are also provided for by the disclosure.

Abstract: Methods for reducing dust emission by coating a seed with a lubricant composition are described herein. The disclosure also provides for a method of reducing insect exposure to vacuum planter dust released during seed planting by applying a lubricant composition to a seed. Methods for increasing seed lubricity by coating a seed with a lubricant composition are also described. Compositions and seeds useful in these methods are also described.

Abstract: Provide herein are methods of treating inflammatory bowel disease with geranylgeranyl acetone (GGA) and/or derivatives thereof. Also provided are methods of treating chronic liver disease (CLD) with geranylgeranyl acetone (GGA) and/or derivatives thereof. Still further are provided methods for treating other hepatic and cardiac disorders.

Abstract: Provide herein are methods for treating osteopenia with geranylgeranyl acetone (GGA) and derivatives thereof and compositions useful for the same.

Abstract: A stable aqueous solution of sodium pyruvate for medical use, which contains 10-1,200 mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H+ which leads to pH 3.0-6.0 or NaCl which provides at least 20 mM Na+.

Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.

Abstract: The invention provides compositions and methods for the treatment of glomerulonephritis. In one embodiment, the invention provides a compound of formula (I) R-L-CO—X??(I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO; and X is an electron withdrawing group) or a salt thereof for use in the treatment of glomerulonephritis.

Abstract: This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.

Abstract: Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4+ and CD8+ T lymphocyte levels, increase immune function, increase immune response against viruses and prevent or ameliorate the Metabolic Syndrome, Type 2 diabetes and obesity by administering orally or parenterally a therapeutically effective amount of punicic acid to the animal.

Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.

Abstract: Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.